DUBLIN, March 3, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) a leading global pharmaceutical company, kicked off their Live Chin Up campaign at an exclusive event at the Frank Gehry-designed IAC Building in New York City today, hosted by television personality and New York Times best-selling author Khloé Kardashian. The Live Chin Up campaign is designed to help encourage people to not let the things that bother them get in their way.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

At the event, Kardashian moderated a distinguished panel of experts which included a dermatologist who discussed submental fullness and treatment options, including KYBELLA^® (deoxycholic acid) injection 10mg/mL. Additionally, a patient joined the panel to discuss her experience living with submental fullness.  

"We are very pleased that Khloé was able to serve as the host of our event and discuss how she lives chin up," said Philippe Schaison, EVP and President Allergan Medical. "As someone who lives life in the public eye, Khloé embodies what it means to live chin up by refusing to let negativity stand in her way. We feel she is the perfect person to kick off this inspiring campaign."

Anyone interested in learning more about this campaign or how they can live chin up can visit www.livechinup.com. To learn more about KYBELLA^® or to find a doctor please visit www.mykybella.com.

KYBELLA^® Important Safety Information

What is KYBELLA^®?

KYBELLA^® is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called "double chin."

It is not known if KYBELLA^® is safe and effective for use outside of the submental area or in children under the age of 18.

Who should not receive KYBELLA^®?

You should not receive KYBELLA^® if you have an infection in the treatment area.

Before receiving KYBELLA^®, tell your healthcare provider about all of your medical conditions, including if you: Have had or plan to have surgery on your face, neck, or chin; have had cosmetic treatments on your face, neck, or chin; have had or have medical conditions in or near the neck area; have had or have trouble swallowing; have bleeding problems; are pregnant or plan to become pregnant (it is not known if KYBELLA^® will harm your unborn baby); are breastfeeding or plan to breastfeed (it is not known if KYBELLA^® passes into your breast milk; talk to your healthcare provider about the best way to feed your baby if you receive KYBELLA^®).

Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take a medicine that prevents the clotting of your blood (antiplatelet or anticoagulant medicine).

What are the possible side effects of KYBELLA^®?

KYBELLA^® can cause serious side effects, including nerve injury in the jaw (which can cause an uneven smile or facial muscle weakness), or trouble swallowing.

The most common side effects of KYBELLA^® include: swelling, bruising, pain, numbness, redness, and areas of hardness in the area. These are not all of the possible side effects of KYBELLA^®. Call your healthcare provider for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/MedWatch or call 1-800-FDA-1088.

Please talk to your healthcare provider or visit www.mykybella.com for full Prescribing Information.

© 2016 Allergan.  All rights reserved.  All trademarks are the property of their respective owners.

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

APC66TU16

CONTACTS:   

Investors: 
Lisa DeFrancesco 
(862) 261-7152

Media:  
Mark Marmur 
(862) 261-7558

Ember Garrett
(714) 246-3525

SOURCE Allergan plc

Related Links

http://www.allergan.com